Prati-Donaduzzi

What Prati-Donaduzzi does

Prati-Donaduzzi is a Brazilian pharmaceutical manufacturer founded in 1993 in Toledo, Western Paraná, by Luiz and Carmen Donaduzzi. The company is Brazil's largest generics pharmaceutical manufacturer by volume, producing approximately 17 billion therapeutic doses annually as of 2024 across a portfolio of 360 generic drug presentations. Generic medicines account for the vast majority of revenues (96.34% as of 2019), with the balance drawn from branded medicines (Similares), over-the-counter (OTC) products, prescription medicines (notably in mental health since 2019), and the Vigora Plus dietary supplement line. The company has extended into higher-value adjacencies including Active Pharmaceutical Ingredient (API) manufacturing, with synthetic Cannabidiol as its pioneering API product, and cannabis-based therapeutics through the Myalo drug for refractory epilepsy, developed in partnership with Hospital das Clínicas of USP (Ribeirão Preto).

The company's technology base is anchored in a high-volume industrial park in Toledo and a dedicated API manufacturing facility in the same city. Operations are certified to US FDA GMP standards, and the dietary supplement line holds NSF International certification, the international gold standard recognized by the US FDA, enabling North American exports since 2018. Prati-Donaduzzi operates three wholly-owned subsidiaries: Centralpack Embalagens (packaging), Serprati (recreational sports society), and Uniprati (corporate university). The Donaduzzi family has separately founded Biopark, a 5-million-square-meter science and technology park focused on AI, biotech, and data science education.

The business model is sales-led and distribution-driven. Products reach consumers through 31 owned distribution units across 25 Brazilian states, supplying more than 55,000 retail pharmacies and 36,000+ public basic health units (SUS), with Prati-Donaduzzi's generics serving approximately 25% of Brazilian diabetics and 12% of hypertensive patients. Generics are priced at least 35% below reference brand medicines. Revenue model is product sale (one-time transaction per unit) across retail pharmacies, government health system procurement, and a small but growing export business. The company reported 2024 revenue of R$2.4 billion with 5,000+ employees and is preparing to enter the GLP-1 weight-loss market (semaglutida) following patent expirations.

Name

Prati-Donaduzzi

Legal name

Prati-Donaduzzi

Website

https://pratidonaduzzi.com.br

Company type

Private

Founded year

1993

Operating status

Operating

Headcount range

101–250 employees

Short description

Prati-Donaduzzi is Brazil's largest generics pharmaceutical manufacturer by volume, producing 17 billion doses annually across 360 generic presentations, serving 55,000+ pharmacies and 36,000+ public health units with affordable medicines for chronic conditions.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Generic Hospital & Institutional Products (HLAIABAL)

akta.pro secondary industries

Primary Care & General Medicine Pharmaceuticals (HLAIAAAA), Generic Tender & Government Supply Markets (HLAIABAM)

Keywords

• Generic pharmaceuticals
• Prescription medicines
• Over-the-counter medicines
• Dietary supplements
• Active pharmaceutical ingredients

Headquarters

HQ city

Toledo

HQ country

Brazil

HQ region

Latin America

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales

Revenue model

1. Pharmaceutical Product Sales: Revenue from selling generic drugs (96.34% of revenues as of 2019), prescription medicines (mental health area since 2019), branded medicines, OTC medicines, and dietary supplements across Brazil and export markets including North America.
2. Export Revenue: Export of dietary supplements to North American market since 2018, with 8 products produced according to client specifications.

Go-to-market motion4 records

Distribution channels4 records

Marketing channels5 records

Core offering

Prati-Donaduzzi is Brazil's largest generics pharmaceutical manufacturer by volume, producing 17 billion doses annually across a portfolio of generic drugs (96.34% of revenues), prescription medicines for mental health, branded generic-equivalent (Similares) medicines, OTC medicines, and a dietary supplement line (Vigora Plus). Products are distributed to 55,000+ pharmacies and 36,000+ basic health units across all 25 Brazilian states, treating approximately 25% of diabetics and 12% of hypertensive patients in Brazil at prices at least 35% below reference brands.

Product overview

Prati-Donaduzzi is a Brazilian pharmaceutical manufacturer specializing in generic drugs, operating as one of Brazil's largest generics producers with a portfolio spanning multiple product lines. The company produces approximately 17 billion therapeutic doses annually (2024 data) and maintains a portfolio of 360 generic drug options. The core product offering consists of Generic Medicines (representing 96.34% of revenues), RX Medicines for Mental Health, Branded Medicines (Similares), Over-the-Counter Medicines, and Dietary Supplements under the Vigora Plus line. Notable branded products include Myalo® (cannabis-based drug for refractory epilepsy), and the company has expanded into Active Pharmaceutical Ingredients (APIs) manufacturing including synthetic Cannabidiol. The company also manufactures generic versions of treatments for chronic conditions including diabetes (serving approximately 25% of diabetics in Brazil) and hypertension (serving approximately 12% of hypertensive patients in Brazil).

Differentiator

Problem solved

Functional benefit

Brands

• Vigora Plus: Dietary supplement product line including omega 3, coconut oil, vitamin D, vitamins and minerals, vitamin E, calcium and vitamin D3, and multivitamins for men and elderly women.
• Myalo

Products and services

• Generic Medicines Generic pharmaceutical drugs with the same quality as reference brands but at prices at least 35% more accessible. Prati-Donaduzzi holds approximately 22% market share of generic drugs produced in Brazil. Targeted at pharmacies and end patients needing affordable chronic and acute condition treatments.
• RX Medicines - Mental Health Prescription medicines focused on mental health conditions including schizophrenia and multiple sclerosis treatments. Targeted at healthcare providers and patients requiring prescription neurological therapies.
• Branded Medicines (Similares) Branded generic-equivalent medicines that are similar to reference products but not interchangeable at the pharmacy level. Distributed through retail pharmacies nationwide.
• Over-the-Counter Medicines (OTC) Medicines that do not require a prescription for purchase, available for self-medication at pharmacies. Targeted at consumers seeking self-treatment options.
• Vigora Plus Dietary Supplements Line Dietary supplement product line including omega 3, coconut oil, vitamin D, vitamins and minerals, vitamin E, calcium and vitamin D3, and multivitamins for men and elderly women. Products are soft gelatin capsules, lactose and gluten free. Sold as 30 products nationally and 8 products exported to North America with NSF International certification meeting US FDA GMP standards.
• Myalo® (Cannabis-Based Drug) Cannabis-based drug indicated for the control of refractory epilepsy crises (most critical grade of the disease, primarily in children). Produced from purified plant extract in partnership with Hospital das Clínicas of USP, campus of Ribeirão Preto. Targeted at approximately 700,000 Brazilians suffering from refractory epilepsy.
• Active Pharmaceutical Ingredients (APIs) Active Pharmaceutical Ingredients (APIs) manufactured at the company's Toledo facility. The product line debuted with innovative synthetic Cannabidiol as the pioneering product, with high purity excluding the presence of psychoactive THC. Enables vertical integration and reduces dependency on external API suppliers.

Quantifiable outcome

• 35% price reduction vs reference brands
• +3 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

14 partnerships are on record, tiered core and minor.

• Hospital das Clínicas of USP (Ribeirão Preto)coreStrategic or Co-development PartnerPartnership for clinical trials and development of Myalo, a cannabis-based drug for refractory epilepsy. Research conducted in partnership with Hospital das Clínicas de USP, campus of Ribeirão Preto. The drug will help improve quality of life of nearly 700,000 people suffering from the disease in the country.
• SENAIcoreStrategic or Co-development PartnerPartnership for technical course in Pharmacy area. SENAI provides theoretical training while Prati-Donaduzzi provides practical training in productive and administrative areas. Course recognized by Ministry of Education (MEC) with 1,200 hours per class.
• SESIminorStrategic or Co-development PartnerPartnership for 'Universe of Science' program that teaches science subjects in innovative ways using dynamic laboratory approach. Sesi provides partnership support for the educational initiative targeting 12-16 year old students.
• Biopark (Bioscience and Technology Park)coreStrategic or Co-development PartnerScience and Technology Park of Biosciences founded by Luiz and Carmen Donaduzzi. 5-million-square-meter private tech and education enclave near Toledo modeled after France's Sophia Antipolis. Aims to house 75,000 residents and generate 30,000 jobs. Initiative focuses on free education and scholarships in AI, biotech, and data science.
• Centralpack EmbalagensminorOthersPackaging industry based in Toledo. Provides packaging materials for Prati-Donaduzzi products including folding cartons and package inserts. Technical visits exchanged between companies to promote integration and quality awareness.
• Abrinq FoundationminorOthersFoundation supporting child rights. Prati-Donaduzzi received 2018 Child Award for Safe Pregnancy program. Foundation provides training on musicalization and donated 40 musical instruments for program activities.
• Toledo City HallminorOthersSupport for Pact for the Child Program through Fund for Children and Adolescents (FIA). Resources allocated to welfare institutions serving children and adolescents in situations of social vulnerability.
• Erasto Gaertner HospitalminorOthersLargest cancer treatment center in Southern Brazil. Prati-Donaduzzi supports 'For the Life of the Elderly in cancer treatment' project. Also hosts Specialists of Joy clown troupe performing for patients.
• Angelina Caron HospitalminorOthersHospital in metropolitan region of Curitiba recognized for care of patients from Public Health System (SUS). Prati-Donaduzzi provides support for studies and improvements in elderly patient care.
• Jaguariense Association of Social Interests (AJIS)minorOthersCivil, philanthropic, charitable and assistance entity. Prati-Donaduzzi supports physical improvements in Long Term institution 'Pequena Casa da Divina Providência' for elderly care.
• Toledo Volleyball Association (Avotol)minorOthersAssociation developing volleyball programs including 'Mais Vôlei Toledo' project assisting over 300 athletes and Beach Volleyball project for 50 athletes. Prati-Donaduzzi provides sponsorship through Sports Incentive Law.
• Primato Cooperativa AgroindustrialminorOthersCooperative in Toledo. Host venue for PAM (Mutual Assistance Plan) meeting celebrating 5 years of the voluntary emergency response program.
• Serprati (Prati-Donaduzzi Recreational Sports Society)minorOthersCompany's recreational sports society managing Serprati Choir and other cultural/sports programs. SCENIC CHOIR-SER PRATI MUSICAL project gives 70+ participants chance to learn music in choral and instrumental format.
• NSF InternationalcoreOthersInternational certification organization providing 'gold standard' dietary supplement certification. Conducts annual inspections verifying compliance with US FDA Good Manufacturing Practice (GMP).

Scale indicators13 records

Recent moves6 records

Expansion highlights5 records

Emerging players

• Torrent Pharmaceuticals: Indian generics manufacturer focused on chronic-disease therapies (cardiovascular, diabetes). Comparable in therapeutic-area emphasis and emerging-market positioning.
• Glenmark Pharmaceuticals: Indian generic pharmaceutical manufacturer with significant emerging-market distribution. Comparable in vertical API integration and emerging-market generics strategy.

Direct peers

• Eurofarma: Major Brazilian pharmaceutical manufacturer with strong generics and branded generics presence across Latin America. Directly comparable in scale, distribution model, and therapeutic area coverage.
• EMS Pharma: Brazil's largest pharmaceutical company by revenue, dominant generics manufacturer. Directly comparable as a Brazilian generics peer with similar pharmacy-channel distribution and chronic-disease portfolio overlap.
• Aché Laboratórios: Brazilian pharmaceutical company with diversified generics and branded prescription portfolio. Comparable in domestic market presence and pharmacy distribution.
• Medley (Sanofi): Brazilian generics leader, now part of Sanofi. Historically a leading domestic generics manufacturer with overlapping pharmacy-channel distribution and cardiovascular portfolio.
• Biolab Farmacêutica: Mid-to-large Brazilian pharmaceutical company with branded generics and specialty prescription portfolio. Comparable in Brazilian market positioning and pharmacy-channel go-to-market.
• Cristália: Brazilian pharmaceutical manufacturer focused on generics, hospital products, and APIs. Closely comparable given its Biocon partnership for semaglutida, competing with Prati-Donaduzzi's planned GLP-1 entry.

Broad incumbents

• Viatris (Mylan): Global generics and specialty pharmaceutical company. Comparable in API+finished-dose generics model and cardiovascular/metabolic therapy presence.
• Teva Pharmaceutical Industries: Global leader in generic pharmaceuticals with broad portfolio across multiple therapeutic areas. Comparable as a high-volume generics manufacturer, though operating at vastly larger global scale.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/user/pratidonaduzzi1
• Facebookfacebook.com/pratidonaduzzi
• Instagraminstagram.com/pratidonaduzzi

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Prati-Donaduzzi